(Q40532095)

21 September 2017

1 reference

title

Use of the elevated plus maze in the search for novel anxiolytic agents (English)

1 reference

21 September 2017

1 reference

Dawson GR

1

1 reference

PubMed ID

7762079

21 September 2017

Tricklebank MD

series ordinal

2

1 reference

21 September 2017

1 February 1995

1 reference

Trends in Pharmacological Sciences

21 September 2017

1 reference

21 September 2017

16

1 reference

21 September 2017

33-36

1 reference

21 September 2017

2

1 reference

The relation between fear induced by novel stimulation and exploratory drive

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

Anxiogenic stimuli in the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

Beware the builders: construction noise changes [14C]GABA release and uptake from amygdaloid and hippocampal slices in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

A comparison between atria from control and streptozotocin-diabetic rats: the effects of dietary myoinositol

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

Trial 2 in the elevated plus-maze: a different form of fear?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2988973-7

7 January 2021

10.1016/S0165-6147(00)88973-7

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

7762079